SuanFarma-Header SuanFarma-Header

X

Find Novel Drugs for Genetic Disease under Development in UNITED KINGDOM

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Cell-penetrating peptides conjugates

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 09, 2020

            Details:

            PepGen will use the funding to advance into the clinic their next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) that are designed to correct genetic defects in diseases with high unmet medical need.